List of Treatments for Amyloidosis

Ninlaro (Ixazomib)

Overview
Ninlaro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with multiple myeloma who have received at least one prior treatment. Ninlaro is sometimes prescribed… read more

Onpattro (Patisiran)

Overview
Onpattro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Onpattro is also… read more

Pomalyst (Pomalidomide)

Overview
Pomalyst is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults and children with multiple myeloma who have received at least two prior therapies. Pomalyst is sometimes… read more

Revlimid (Lenalidomide)

Overview
Revlimid is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with multiple myeloma or various forms of lymphoma. Revlimid is sometimes prescribed off-label to treat… read more

Tegsedi (Inotersen)

The Tegsedi brand name has been discontinued in the U.S. Generic alternatives may be available.

Overview
Tegsedi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve…

Thalidomid (Thalidomide)

Overview
Thalidomid is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults and children with newly diagnosed multiple myeloma or erythema nodosum leprosum on the skin. Thalidomid… read more

Velcade (Bortezomib)

Overview
Velcade is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with multiple myeloma or mantle cell lymphoma. Velcade is sometimes prescribed off-label to treat… read more

Vyndaqel (Tafamidis meglumine)

Overview
Vyndaqel is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with heart disease resulting from wild-type or hereditary (hATTR) amyloidosis. Vyndaqel is also referred… read more

Wainua (Eplontersen)

Overview
Wainua is approved by the U.S. Food and Drug Administration (FDA) for the treatment of polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated amyloidosis in adults. This medication is…